Key Drivers
- Strong Net Cash
- Persistent Cash Burn
- Meaningful Dilution
AIAI Summary
CADL is now primarily a regulatory-execution bet on CAN-2409's reported positive Phase III prostate data, but investors should wait for reconciled trial status, a defined BLA/manufacturing path, and controlled cash burn before underwriting approval-driven upside, as dilution and regulatory delays could overwhelm its $202M cash cushion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Net Cash
- •Persistent Cash Burn
- •Meaningful Dilution
CADL's sizable net cash position supports liquidity, but zero revenue, heavy cash burn, dilution, and a high valuation make the shares high-risk.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support tested
- •Resistance overhead
CADL remains bearish over the last month, with support at $10.55–$10.68 needing to hold and a sustained break above $11.34 required to improve momentum.
Sharp drop from the $13.75 late-August high indicates elevated volatility
Sentiment & News
Key News Insights:
- •Board Expansion
- •Employee Grants
- •Investor Conferences
Candel Therapeutics' updates signal corporate expansion and investor engagement, but no new clinical catalysts.
Near-term impact appears neutral absent fresh clinical or regulatory data
Similar Companies in Healthcare
Other companies in the same sector with AI ratings